CancerDrs

Lung Cancer clinical trials in California

114 actively recruiting lung cancer trials at 105 sites across California.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in California:
  • Kaiser Permanente-Anaheim — Anaheim, California
  • Kaiser Permanente-Deer Valley Medical Center — Antioch, California
  • PCR Oncology — Arroyo Grande, California
  • Sutter Auburn Faith Hospital — Auburn, California
  • Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in California:
  • Tower Cancer Research Foundation — Beverly Hills, California
  • Kaiser Permanente Dublin — Dublin, California
  • Kaiser Permanente-Fremont — Fremont, California
  • Kaiser Permanente Fresno Orchard Plaza — Fresno, California
  • UC San Diego Moores Cancer Center — La Jolla, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Sites in California:
  • Oncura Health - Anaheim — Anaheim, California
  • Memorial Care Orange Coast Medical Center Attn — Fountain Valley, California
  • MemorialCare Orange Coast Medical Center — Fountain Valley, California
  • OC Blood and Cancer Care — Fountain Valley, California
  • Oncura Health - Fountain Valley — Fountain Valley, California
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in California:
  • Tower Cancer Research Foundation — Beverly Hills, California
  • Cedars-Sinai Medical Center — Los Angeles, California
  • Cedars-Sinai Cancer - Tarzana — Tarzana, California
  • Torrance Memorial Physician Network - Cancer Care — Torrance, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in California:
  • Cedars-Sinai Medical Center — Los Angeles, California
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Torrance, California
  • BASS Cancer Center — Walnut Creek, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in California:
  • Research Site — Anaheim, California
  • Research Site — Beverly Hills, California
  • Research Site — Loma Linda, California
  • Research Site — Los Alamitos, California
  • Research Site — Redlands, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in California:
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • City of Hope at Irvine Lennar — Irvine, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in California:
  • Local Institution - 0112 — Los Angeles, California
  • University of California Davis (UC Davis) Comprehensive Cancer Center — Sacramento, California
  • Local Institution - 0159 — San Francisco, California
  • UCLA Hematology/Oncology - Santa Monica — Santa Monica, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in California:
  • Providence St. Jude Medical Center ( Site 0106) — Fullerton, California
  • VA Long Beach Healthcare System ( Site 0199) — Long Beach, California
  • USC Norris Comprehensive Cancer Center ( Site 0205) — Los Angeles, California
  • UCLA Jonsson Comprehensive Cancer Center ( Site 0135) — Los Angeles, California
  • UCSF Medical Center at Mission Bay ( Site 0178) — San Francisco, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in California:
  • John Muir Clinical Research Center — Concord, California
  • University Of California - San Diego Moores Cancer Center — La Jolla, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT04928846
Sites in California:
  • City of Hope /ID# 243157 — Duarte, California
  • City Of Hope - Seacliff /ID# 263143 — Huntington Beach, California
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 263144 — Irvine, California
  • City Of Hope - Antelope Valley /ID# 263138 — Lancaster, California
  • The Oncology Institute Of Hope & Innovation -East Los A /ID# 239774 — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in California:
  • Beverly Hills Cancer Center — Beverly Hills, California
  • Orange Coast Memorial Medical Center — Fountain Valley, California
  • Local Institution - 0027 — Los Alamitos, California
  • Local Institution - 0422 — Los Angeles, California
  • Pacific Cancer Care — Monterey, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in California:
  • Research Site — La Mesa, California
  • Research Site — Los Alamitos, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…

Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in California:
  • St. Jude Herritage Medical Group — Fullerton, California
  • Hoag Family Cancer Institute - Hoag Memorial Hospital — Newport Beach, California
  • Sutter Institute for Medical Research — Sacramento, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).

Sponsor: Taiho Oncology, Inc.
NCT ID: NCT07128199
Sites in California:
  • City of Hope Comprehensive Cancer Center - Duarte — Duarte, California
  • City of Hope Comprehensive Cancer Center Orange County Lennar Foundation Cancer Center — Irvine, California
  • Scripps Clinic Torrey Pines — La Jolla, California
  • Kaiser Permanente - Vallejo Medical Center — Vallejo, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a…

Sponsor: AbbVie
NCT ID: NCT07155187
Sites in California:
  • City of Hope National Medical Center /ID# 277005 — Duarte, California
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277928 — Irvine, California
  • UC San Diego Health - Moores Cancer Center /ID# 278836 — La Jolla, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Sponsor: Eikon Therapeutics
NCT ID: NCT07365319
Sites in California:
  • Los Angeles Cancer Network — Glendale, California
  • Providence St. Joseph Hospital — Orange, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-…

Sponsor: SystImmune Inc.
NCT ID: NCT07625644
Sites in California:
  • OPN Healthcare — Glendale, California
  • MemorialCare Todd Cancer Institute — Long Beach, California
  • Valkyrie Clinical Trials — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aim…

Sponsor: GlaxoSmithKline
NCT ID: NCT07099898
Sites in California:
  • GSK Investigational Site — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in California:
  • Kaiser Permanente-Anaheim — Anaheim, California
  • Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
  • PCR Oncology — Arroyo Grande, California
  • Sutter Auburn Faith Hospital — Auburn, California
  • Kaiser Permanente-Baldwin Park — Baldwin Park, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03191149
Sites in California:
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07293247
Sites in California:
  • USC / Norris Comprehensive Cancer Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in California:
  • University of California Los Angeles Medical Center — Los Angeles, California
  • University of California, San Diego; Moores Cancer Center — San Diego, California
  • USOR Sansum Clinic — Santa Barbara, California
  • Providence Medical Foundation — Santa Rosa, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a…

Sponsor: Synthekine
NCT ID: NCT05098132
Sites in California:
  • Beverly Hills Cancer Center — Beverly Hills, California
  • Providence Medical Foundation — Fullerton, California
  • UC San Diego Moores Cancer Center — La Jolla, California
  • Cedars Sinai — Los Angeles, California
  • Hoag Memorial Hospital Presbyterian — Newport Beach, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…

Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in California:
  • Kadima Neuropsychiatry Institute — San Diego, California
  • Providence Medical Foundation — Santa Rosa, California
View on ClinicalTrials.gov →

Showing 25 of 114 trials with sites in California. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19